Yilong Zhang, Ph.D.
Affiliations: | 2002 | Ohio State University, Columbus, Columbus, OH |
Area:
Pharmacy, Pharmacology, Oncology, Molecular BiologyGoogle:
"Yilong Zhang"Parents
Sign in to add mentor| Jessie L. Au | grad student | 2002 | Ohio State | |
| (Induction of FGF as a mechanism of acquired anticancer drug resistance.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Doi T, Yamaguchi K, Komatsu Y, et al. (2017) A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Japanese Journal of Clinical Oncology. 1-8 |
| Glisson B, Besse B, Dols MC, et al. (2017) A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer |
| Villalona-Calero MA, Otterson GA, Wientjes MG, et al. (2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1903-9 |
| Zhang Y, Song S, Yang F, et al. (2001) Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. The Journal of Pharmacology and Experimental Therapeutics. 299: 426-33 |